Share Price and Basic Stock Data
Last Updated: November 3, 2025, 8:25 pm
| PEG Ratio | -5.15 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Chemfab Alkalis Ltd operates primarily in the inorganic chemicals sector, focusing on the production of caustic soda and soda ash. The company’s stock is currently priced at ₹606, with a market capitalization of ₹871 Cr. Over the past fiscal year, Chemfab reported sales of ₹331 Cr, which showed a consistent growth trajectory from ₹272 Cr in FY 2022. The trailing twelve months (TTM) sales stood at ₹334 Cr, indicating a slight decline compared to the previous fiscal year. Quarterly sales figures exhibited fluctuations, with the highest quarterly sales of ₹98.11 Cr recorded in June 2022, followed by a dip to ₹73.30 Cr in March 2023. However, the company has shown resilience, rebounding to ₹79.58 Cr in September 2023. The overall sales growth reflects the company’s ability to navigate through varied market conditions, positioning it strategically within the chemical industry.
Profitability and Efficiency Metrics
Chemfab Alkalis Ltd’s profitability metrics reveal a mixed performance. The operating profit margin (OPM) stood at 15.32%, which is considerably lower than the historical highs of 36.21% in June 2022. The net profit for the most recent fiscal year was ₹66 Cr, translating to an EPS of ₹46.69, although the latest quarter’s net profit fell to ₹5.39 Cr with an EPS of ₹3.75. The interest coverage ratio (ICR) was robust at 10.32x, showcasing the company’s capacity to meet its interest obligations comfortably, although it has declined from previous higher levels. Efficiency indicators such as the cash conversion cycle (CCC) improved to -12 days, reflecting effective management of working capital. However, the return on equity (ROE) at 3.69% and return on capital employed (ROCE) at 5.89% indicate that the company has room for improvement in generating returns relative to shareholder equity and capital employed.
Balance Sheet Strength and Financial Ratios
The balance sheet of Chemfab Alkalis Ltd reveals a mixed picture of financial health. As of FY 2025, the company reported total borrowings of ₹84 Cr against reserves of ₹393 Cr, suggesting a relatively low debt burden. The debt-to-equity ratio stood at 0.21, indicating conservative leverage compared to industry norms. The current ratio of 1.65 suggests adequate liquidity to cover short-term obligations, while the quick ratio of 1.28 further confirms financial stability. However, the book value per share decreased slightly to ₹264.55, indicating a potential erosion in net asset value. The price-to-book value (P/BV) ratio was recorded at 2.67x, which may suggest overvaluation compared to the sector average, typically ranging from 1.5x to 2.5x for chemical firms. Overall, while Chemfab exhibits a solid capital structure, the declining book value warrants closer scrutiny.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemfab Alkalis Ltd indicates a strong promoter presence, holding 72.18% of the equity, which reflects confidence from the founders in the company’s future. The public shareholding stood at 27.53%, with institutional investors (FIIs and DIIs) holding negligible stakes of 0.01% and 0.27%, respectively. This low institutional interest may suggest a lack of confidence from institutional investors, which could impact the stock’s liquidity and market perception. The number of shareholders increased to 11,586, indicating growing retail interest, although the proportion of public holdings relative to total equity remains modest. The gradual decline in FII participation from 0.38% in September 2022 to 0.01% in June 2025 raises concerns about the stock’s attractiveness to foreign investors, potentially reflecting broader market trends or company-specific issues.
Outlook, Risks, and Final Insight
The outlook for Chemfab Alkalis Ltd hinges on several factors, including market conditions in the chemicals sector and operational efficiencies. The company’s ability to stabilize and grow its sales amid fluctuating demand will be crucial. Risks include the declining profitability margins and low ROE, which may deter potential investors. Additionally, the company’s heavy reliance on domestic markets could expose it to regional economic downturns. However, strengths such as a low debt-to-equity ratio and a strong promoter holding provide a cushion against market volatility. If Chemfab can enhance its operational efficiencies and restore profitability, it may attract greater investor interest. Conversely, failure to address profitability challenges may hinder future growth, necessitating strategic adjustments to capitalize on market opportunities.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemfab Alkalis Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Caprolactam Chemicals Ltd | 20.8 Cr. | 45.2 | 65.0/37.5 | 10.5 | 0.00 % | 0.48 % | 13.7 % | 10.0 | |
| Standard Industries Ltd | 120 Cr. | 18.6 | 31.1/17.4 | 20.4 | 0.00 % | 7.81 % | 10.5 % | 5.00 | |
| Gujarat Alkalies & Chemicals Ltd | 4,134 Cr. | 562 | 894/484 | 772 | 2.81 % | 0.34 % | 1.13 % | 10.0 | |
| GHCL Ltd | 5,953 Cr. | 620 | 779/511 | 10.4 | 378 | 1.93 % | 24.2 % | 18.6 % | 10.0 |
| Tata Chemicals Ltd | 22,298 Cr. | 875 | 1,159/756 | 68.4 | 877 | 1.26 % | 3.96 % | 1.20 % | 10.0 |
| Industry Average | 6,670.80 Cr | 451.80 | 45.23 | 390.98 | 1.04% | 7.11% | 8.14% | 9.17 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 98.11 | 76.01 | 83.94 | 73.30 | 79.08 | 79.58 | 86.33 | 82.30 | 76.04 | 79.00 | 79.21 | 87.85 | 87.58 |
| Expenses | 62.58 | 49.98 | 58.40 | 48.19 | 63.14 | 67.44 | 69.94 | 69.13 | 65.59 | 66.34 | 64.72 | 72.16 | 74.16 |
| Operating Profit | 35.53 | 26.03 | 25.54 | 25.11 | 15.94 | 12.14 | 16.39 | 13.17 | 10.45 | 12.66 | 14.49 | 15.69 | 13.42 |
| OPM % | 36.21% | 34.25% | 30.43% | 34.26% | 20.16% | 15.26% | 18.99% | 16.00% | 13.74% | 16.03% | 18.29% | 17.86% | 15.32% |
| Other Income | 0.64 | -2.25 | 2.10 | 1.45 | 3.58 | 1.19 | 1.25 | 1.76 | 2.57 | 0.59 | 1.42 | 1.27 | 1.06 |
| Interest | 0.12 | 0.04 | 0.04 | 0.04 | 0.04 | 0.06 | 0.43 | 0.41 | 0.51 | 1.22 | 1.63 | 1.56 | 1.56 |
| Depreciation | 5.89 | 5.85 | 5.71 | 5.44 | 5.39 | 5.59 | 5.40 | 5.47 | 6.41 | 7.82 | 8.51 | 9.64 | 5.38 |
| Profit before tax | 30.16 | 17.89 | 21.89 | 21.08 | 14.09 | 7.68 | 11.81 | 9.05 | 6.10 | 4.21 | 5.77 | 5.76 | 7.54 |
| Tax % | 28.88% | 26.05% | 28.32% | 24.86% | 29.67% | 30.34% | 30.91% | 27.40% | 29.18% | 29.93% | 30.16% | 31.77% | 28.38% |
| Net Profit | 21.46 | 13.23 | 15.68 | 15.84 | 9.91 | 5.35 | 8.16 | 6.56 | 4.33 | 2.95 | 4.02 | 3.93 | 5.39 |
| EPS in Rs | 15.18 | 9.36 | 11.09 | 11.17 | 6.98 | 3.77 | 5.74 | 4.61 | 3.03 | 2.06 | 2.81 | 2.74 | 3.75 |
Last Updated: August 1, 2025, 10:45 pm
Below is a detailed analysis of the quarterly data for Chemfab Alkalis Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 87.58 Cr.. The value appears to be declining and may need further review. It has decreased from 87.85 Cr. (Mar 2025) to 87.58 Cr., marking a decrease of 0.27 Cr..
- For Expenses, as of Jun 2025, the value is 74.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 72.16 Cr. (Mar 2025) to 74.16 Cr., marking an increase of 2.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 13.42 Cr.. The value appears to be declining and may need further review. It has decreased from 15.69 Cr. (Mar 2025) to 13.42 Cr., marking a decrease of 2.27 Cr..
- For OPM %, as of Jun 2025, the value is 15.32%. The value appears to be declining and may need further review. It has decreased from 17.86% (Mar 2025) to 15.32%, marking a decrease of 2.54%.
- For Other Income, as of Jun 2025, the value is 1.06 Cr.. The value appears to be declining and may need further review. It has decreased from 1.27 Cr. (Mar 2025) to 1.06 Cr., marking a decrease of 0.21 Cr..
- For Interest, as of Jun 2025, the value is 1.56 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 1.56 Cr..
- For Depreciation, as of Jun 2025, the value is 5.38 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.64 Cr. (Mar 2025) to 5.38 Cr., marking a decrease of 4.26 Cr..
- For Profit before tax, as of Jun 2025, the value is 7.54 Cr.. The value appears strong and on an upward trend. It has increased from 5.76 Cr. (Mar 2025) to 7.54 Cr., marking an increase of 1.78 Cr..
- For Tax %, as of Jun 2025, the value is 28.38%. The value appears to be improving (decreasing) as expected. It has decreased from 31.77% (Mar 2025) to 28.38%, marking a decrease of 3.39%.
- For Net Profit, as of Jun 2025, the value is 5.39 Cr.. The value appears strong and on an upward trend. It has increased from 3.93 Cr. (Mar 2025) to 5.39 Cr., marking an increase of 1.46 Cr..
- For EPS in Rs, as of Jun 2025, the value is 3.75. The value appears strong and on an upward trend. It has increased from 2.74 (Mar 2025) to 3.75, marking an increase of 1.01.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 5:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 30 | 25 | 140 | 180 | 193 | 205 | 181 | 272 | 331 | 327 | 322 | 334 |
| Expenses | 23 | 29 | 18 | 108 | 128 | 133 | 149 | 157 | 215 | 219 | 269 | 268 | 277 |
| Operating Profit | -3 | 0 | 7 | 32 | 52 | 61 | 56 | 24 | 57 | 112 | 58 | 54 | 56 |
| OPM % | -13% | 1% | 27% | 23% | 29% | 31% | 27% | 13% | 21% | 34% | 18% | 17% | 17% |
| Other Income | 3 | 3 | 0 | 2 | 4 | -15 | -0 | 1 | 6 | 2 | 8 | 6 | 4 |
| Interest | 8 | 7 | 3 | 5 | 4 | 2 | 4 | 3 | 1 | 1 | 1 | 5 | 6 |
| Depreciation | 3 | 4 | 4 | 13 | 12 | 15 | 25 | 20 | 22 | 23 | 22 | 32 | 31 |
| Profit before tax | -10 | -7 | 0 | 16 | 40 | 28 | 27 | 2 | 39 | 91 | 43 | 22 | 23 |
| Tax % | 0% | 0% | 0% | 6% | 36% | 41% | 5% | 479% | 26% | 27% | 30% | 30% | |
| Net Profit | -10 | -7 | 0 | 16 | 25 | 17 | 26 | -8 | 29 | 66 | 30 | 15 | 16 |
| EPS in Rs | 18.42 | 12.07 | 18.36 | -5.72 | 20.40 | 46.69 | 21.08 | 10.60 | 11.36 | ||||
| Dividend Payout % | 0% | 0% | 0% | 11% | 7% | 10% | 7% | 0% | 6% | 3% | 6% | 12% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 30.00% | 100.00% | 56.25% | -32.00% | 52.94% | -130.77% | 462.50% | 127.59% | -54.55% | -50.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 70.00% | -43.75% | -88.25% | 84.94% | -183.71% | 593.27% | -334.91% | -182.13% | 4.55% |
Chemfab Alkalis Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | 3% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | -12% |
| 3 Years: | -20% |
| TTM: | -33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 36% |
| 3 Years: | 23% |
| 1 Year: | -26% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 8% |
| 3 Years: | 10% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 1:55 am
Balance Sheet
Last Updated: June 16, 2025, 12:18 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 7 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |
| Reserves | -17 | -24 | -17 | 201 | 222 | 237 | 262 | 254 | 284 | 349 | 379 | 393 |
| Borrowings | 76 | 82 | 66 | 16 | 23 | 34 | 43 | 31 | 9 | 2 | 20 | 84 |
| Other Liabilities | 10 | 10 | 14 | 44 | 39 | 36 | 30 | 36 | 45 | 48 | 85 | 54 |
| Total Liabilities | 75 | 73 | 70 | 275 | 298 | 321 | 348 | 335 | 352 | 413 | 498 | 546 |
| Fixed Assets | 64 | 61 | 57 | 164 | 173 | 194 | 195 | 202 | 194 | 191 | 181 | 249 |
| CWIP | 0 | 0 | 1 | 11 | 2 | 10 | 35 | 3 | 7 | 14 | 57 | 12 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 31 | 42 | 110 | 110 | 164 |
| Other Assets | 10 | 12 | 12 | 99 | 124 | 117 | 110 | 98 | 109 | 98 | 150 | 121 |
| Total Assets | 75 | 73 | 70 | 275 | 298 | 321 | 348 | 335 | 352 | 413 | 498 | 546 |
Below is a detailed analysis of the balance sheet data for Chemfab Alkalis Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
- For Reserves, as of Mar 2025, the value is 393.00 Cr.. The value appears strong and on an upward trend. It has increased from 379.00 Cr. (Mar 2024) to 393.00 Cr., marking an increase of 14.00 Cr..
- For Borrowings, as of Mar 2025, the value is 84.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 20.00 Cr. (Mar 2024) to 84.00 Cr., marking an increase of 64.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 54.00 Cr.. The value appears to be improving (decreasing). It has decreased from 85.00 Cr. (Mar 2024) to 54.00 Cr., marking a decrease of 31.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 546.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 498.00 Cr. (Mar 2024) to 546.00 Cr., marking an increase of 48.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 249.00 Cr.. The value appears strong and on an upward trend. It has increased from 181.00 Cr. (Mar 2024) to 249.00 Cr., marking an increase of 68.00 Cr..
- For CWIP, as of Mar 2025, the value is 12.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2024) to 12.00 Cr., marking a decrease of 45.00 Cr..
- For Investments, as of Mar 2025, the value is 164.00 Cr.. The value appears strong and on an upward trend. It has increased from 110.00 Cr. (Mar 2024) to 164.00 Cr., marking an increase of 54.00 Cr..
- For Other Assets, as of Mar 2025, the value is 121.00 Cr.. The value appears to be declining and may need further review. It has decreased from 150.00 Cr. (Mar 2024) to 121.00 Cr., marking a decrease of 29.00 Cr..
- For Total Assets, as of Mar 2025, the value is 546.00 Cr.. The value appears strong and on an upward trend. It has increased from 498.00 Cr. (Mar 2024) to 546.00 Cr., marking an increase of 48.00 Cr..
Notably, the Reserves (393.00 Cr.) exceed the Borrowings (84.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -79.00 | -82.00 | -59.00 | 16.00 | 29.00 | 27.00 | 13.00 | -7.00 | 48.00 | 110.00 | 38.00 | -30.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 49 | 42 | 9 | 22 | 35 | 31 | 17 | 31 | 29 | 24 | 24 | 23 |
| Inventory Days | 341 | 320 | 203 | 152 | 84 | 79 | 54 | 89 | 58 | 99 | ||
| Days Payable | 320 | 64 | 546 | 225 | 164 | 156 | 92 | 145 | 101 | 133 | ||
| Cash Conversion Cycle | 70 | 298 | -334 | 22 | 35 | -43 | -63 | -47 | -9 | -32 | -20 | -12 |
| Working Capital Days | -230 | -208 | -329 | -25 | -31 | 10 | -2 | 15 | 5 | 8 | -29 | -16 |
| ROCE % | -4% | -0% | 6% | 15% | 17% | 18% | 11% | 2% | 13% | 28% | 11% | 6% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -4.86 | 18.53 | 45.61 | 20.36 | -5.81 |
| Diluted EPS (Rs.) | -4.84 | 18.34 | 45.14 | 20.36 | -5.81 |
| Cash EPS (Rs.) | 20.46 | 34.21 | 61.71 | 36.06 | 8.60 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 264.55 | 271.92 | 254.72 | 210.84 | 190.09 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 264.55 | 271.92 | 254.72 | 210.84 | 190.09 |
| Revenue From Operations / Share (Rs.) | 232.79 | 230.06 | 233.65 | 192.16 | 128.60 |
| PBDIT / Share (Rs.) | 35.39 | 43.89 | 81.79 | 44.10 | 17.57 |
| PBIT / Share (Rs.) | 10.10 | 28.18 | 65.62 | 28.38 | 3.18 |
| PBT / Share (Rs.) | -0.21 | 27.52 | 63.06 | 27.66 | 1.44 |
| Net Profit / Share (Rs.) | -4.83 | 18.50 | 45.54 | 20.34 | -5.78 |
| NP After MI And SOA / Share (Rs.) | -4.83 | 18.50 | 45.54 | 20.34 | -5.78 |
| PBDIT Margin (%) | 15.20 | 19.07 | 35.00 | 22.95 | 13.65 |
| PBIT Margin (%) | 4.33 | 12.24 | 28.08 | 14.77 | 2.47 |
| PBT Margin (%) | -0.09 | 11.96 | 26.99 | 14.39 | 1.12 |
| Net Profit Margin (%) | -2.07 | 8.04 | 19.49 | 10.58 | -4.49 |
| NP After MI And SOA Margin (%) | -2.07 | 8.04 | 19.49 | 10.58 | -4.49 |
| Return on Networth / Equity (%) | -1.82 | 6.80 | 17.87 | 9.64 | -3.04 |
| Return on Capital Employeed (%) | 3.22 | 9.81 | 25.41 | 13.30 | 1.52 |
| Return On Assets (%) | -1.33 | 5.26 | 15.67 | 8.16 | -2.42 |
| Long Term Debt / Equity (X) | 0.16 | 0.04 | 0.00 | 0.00 | 0.08 |
| Total Debt / Equity (X) | 0.21 | 0.04 | 0.00 | 0.02 | 0.11 |
| Asset Turnover Ratio (%) | 0.65 | 0.71 | 0.86 | 0.79 | 0.52 |
| Current Ratio (X) | 1.65 | 1.09 | 2.71 | 1.82 | 1.83 |
| Quick Ratio (X) | 1.28 | 0.92 | 2.34 | 1.58 | 1.60 |
| Inventory Turnover Ratio (X) | 15.48 | 4.47 | 3.36 | 4.62 | 2.85 |
| Dividend Payout Ratio (NP) (%) | -25.71 | 6.73 | 2.73 | 0.00 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 6.07 | 3.64 | 2.01 | 0.00 | 0.00 |
| Earning Retention Ratio (%) | 125.71 | 93.27 | 97.27 | 0.00 | 0.00 |
| Cash Earning Retention Ratio (%) | 93.93 | 96.36 | 97.99 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 10.32 | 66.27 | 473.83 | 61.54 | 10.07 |
| Interest Coverage Ratio (Post Tax) (X) | 1.60 | 28.94 | 278.63 | 29.38 | -2.32 |
| Enterprise Value (Cr.) | 1091.47 | 916.08 | 314.58 | 353.32 | 204.65 |
| EV / Net Operating Revenue (X) | 3.26 | 2.80 | 0.94 | 1.30 | 1.13 |
| EV / EBITDA (X) | 21.47 | 14.67 | 2.71 | 5.67 | 8.29 |
| MarketCap / Net Operating Revenue (X) | 3.03 | 2.82 | 0.96 | 1.30 | 0.97 |
| Retention Ratios (%) | 125.71 | 93.26 | 97.26 | 0.00 | 0.00 |
| Price / BV (X) | 2.67 | 2.38 | 0.88 | 1.19 | 0.66 |
| Price / Net Operating Revenue (X) | 3.03 | 2.82 | 0.96 | 1.30 | 0.97 |
| EarningsYield | -0.01 | 0.02 | 0.20 | 0.08 | -0.04 |
After reviewing the key financial ratios for Chemfab Alkalis Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -4.86. This value is below the healthy minimum of 5. It has decreased from 18.53 (Mar 24) to -4.86, marking a decrease of 23.39.
- For Diluted EPS (Rs.), as of Mar 25, the value is -4.84. This value is below the healthy minimum of 5. It has decreased from 18.34 (Mar 24) to -4.84, marking a decrease of 23.18.
- For Cash EPS (Rs.), as of Mar 25, the value is 20.46. This value is within the healthy range. It has decreased from 34.21 (Mar 24) to 20.46, marking a decrease of 13.75.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 264.55. It has decreased from 271.92 (Mar 24) to 264.55, marking a decrease of 7.37.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 232.79. It has increased from 230.06 (Mar 24) to 232.79, marking an increase of 2.73.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 35.39. This value is within the healthy range. It has decreased from 43.89 (Mar 24) to 35.39, marking a decrease of 8.50.
- For PBIT / Share (Rs.), as of Mar 25, the value is 10.10. This value is within the healthy range. It has decreased from 28.18 (Mar 24) to 10.10, marking a decrease of 18.08.
- For PBT / Share (Rs.), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0. It has decreased from 27.52 (Mar 24) to -0.21, marking a decrease of 27.73.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -4.83. This value is below the healthy minimum of 2. It has decreased from 18.50 (Mar 24) to -4.83, marking a decrease of 23.33.
- For PBDIT Margin (%), as of Mar 25, the value is 15.20. This value is within the healthy range. It has decreased from 19.07 (Mar 24) to 15.20, marking a decrease of 3.87.
- For PBIT Margin (%), as of Mar 25, the value is 4.33. This value is below the healthy minimum of 10. It has decreased from 12.24 (Mar 24) to 4.33, marking a decrease of 7.91.
- For PBT Margin (%), as of Mar 25, the value is -0.09. This value is below the healthy minimum of 10. It has decreased from 11.96 (Mar 24) to -0.09, marking a decrease of 12.05.
- For Net Profit Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 5. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -2.07. This value is below the healthy minimum of 8. It has decreased from 8.04 (Mar 24) to -2.07, marking a decrease of 10.11.
- For Return on Networth / Equity (%), as of Mar 25, the value is -1.82. This value is below the healthy minimum of 15. It has decreased from 6.80 (Mar 24) to -1.82, marking a decrease of 8.62.
- For Return on Capital Employeed (%), as of Mar 25, the value is 3.22. This value is below the healthy minimum of 10. It has decreased from 9.81 (Mar 24) to 3.22, marking a decrease of 6.59.
- For Return On Assets (%), as of Mar 25, the value is -1.33. This value is below the healthy minimum of 5. It has decreased from 5.26 (Mar 24) to -1.33, marking a decrease of 6.59.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 0.2. It has increased from 0.04 (Mar 24) to 0.16, marking an increase of 0.12.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has increased from 0.04 (Mar 24) to 0.21, marking an increase of 0.17.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.65. It has decreased from 0.71 (Mar 24) to 0.65, marking a decrease of 0.06.
- For Current Ratio (X), as of Mar 25, the value is 1.65. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 1.65, marking an increase of 0.56.
- For Quick Ratio (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 1.28, marking an increase of 0.36.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 15.48. This value exceeds the healthy maximum of 8. It has increased from 4.47 (Mar 24) to 15.48, marking an increase of 11.01.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -25.71. This value is below the healthy minimum of 20. It has decreased from 6.73 (Mar 24) to -25.71, marking a decrease of 32.44.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 6.07. This value is below the healthy minimum of 20. It has increased from 3.64 (Mar 24) to 6.07, marking an increase of 2.43.
- For Earning Retention Ratio (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.27 (Mar 24) to 125.71, marking an increase of 32.44.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 93.93. This value exceeds the healthy maximum of 70. It has decreased from 96.36 (Mar 24) to 93.93, marking a decrease of 2.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 10.32. This value is within the healthy range. It has decreased from 66.27 (Mar 24) to 10.32, marking a decrease of 55.95.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 3. It has decreased from 28.94 (Mar 24) to 1.60, marking a decrease of 27.34.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,091.47. It has increased from 916.08 (Mar 24) to 1,091.47, marking an increase of 175.39.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.26. This value exceeds the healthy maximum of 3. It has increased from 2.80 (Mar 24) to 3.26, marking an increase of 0.46.
- For EV / EBITDA (X), as of Mar 25, the value is 21.47. This value exceeds the healthy maximum of 15. It has increased from 14.67 (Mar 24) to 21.47, marking an increase of 6.80.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
- For Retention Ratios (%), as of Mar 25, the value is 125.71. This value exceeds the healthy maximum of 70. It has increased from 93.26 (Mar 24) to 125.71, marking an increase of 32.45.
- For Price / BV (X), as of Mar 25, the value is 2.67. This value is within the healthy range. It has increased from 2.38 (Mar 24) to 2.67, marking an increase of 0.29.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.03. This value exceeds the healthy maximum of 3. It has increased from 2.82 (Mar 24) to 3.03, marking an increase of 0.21.
- For EarningsYield, as of Mar 25, the value is -0.01. This value is below the healthy minimum of 5. It has decreased from 0.02 (Mar 24) to -0.01, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemfab Alkalis Ltd:
- Net Profit Margin: -2.07%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 3.22% (Industry Average ROCE: 7.11%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -1.82% (Industry Average ROE: 8.14%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.6
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.28
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 56.9 (Industry average Stock P/E: 45.23)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.21
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -2.07%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Caustic Soda/Soda Ash | Team House, GST Salai, Chennai (Madras) Tamil Nadu 600048 | chemfabmktg@ccal.in http://www.chemfabalkalis.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Suresh Krishnamurthi Rao | Chairman & Non-Exe.Director |
| Mr. C S Ramesh | Non Executive Director |
| Mr. R Mahendran | Non Executive Director |
| Mr. Nitin S Cowlagi | Non Executive Director |
| Mrs. Sujatha Jayarajan | Independent Director |
| Mr. A Janakiraman | Independent Director |
| Mrs. Drushti Desai | Independent Director |
| Mr. Satish Narain Jajoo | Independent Director |
FAQ
What is the intrinsic value of Chemfab Alkalis Ltd?
Chemfab Alkalis Ltd's intrinsic value (as of 03 November 2025) is 484.77 which is 17.84% lower the current market price of 590.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 849 Cr. market cap, FY2025-2026 high/low of 1,194/565, reserves of ₹393 Cr, and liabilities of 546 Cr.
What is the Market Cap of Chemfab Alkalis Ltd?
The Market Cap of Chemfab Alkalis Ltd is 849 Cr..
What is the current Stock Price of Chemfab Alkalis Ltd as on 03 November 2025?
The current stock price of Chemfab Alkalis Ltd as on 03 November 2025 is 590.
What is the High / Low of Chemfab Alkalis Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Chemfab Alkalis Ltd stocks is 1,194/565.
What is the Stock P/E of Chemfab Alkalis Ltd?
The Stock P/E of Chemfab Alkalis Ltd is 56.9.
What is the Book Value of Chemfab Alkalis Ltd?
The Book Value of Chemfab Alkalis Ltd is 288.
What is the Dividend Yield of Chemfab Alkalis Ltd?
The Dividend Yield of Chemfab Alkalis Ltd is 0.21 %.
What is the ROCE of Chemfab Alkalis Ltd?
The ROCE of Chemfab Alkalis Ltd is 5.89 %.
What is the ROE of Chemfab Alkalis Ltd?
The ROE of Chemfab Alkalis Ltd is 3.69 %.
What is the Face Value of Chemfab Alkalis Ltd?
The Face Value of Chemfab Alkalis Ltd is 10.0.